If confirmed, evidence of a beneficial effect of tirzepatide on renal endpoints would enable clinical and translational research on the relationship between GIP and the kidney, and the pure renal effect of GIP agonism. Heerspink and colleagues’ hypothesis of a role of the perirenal adipose tissue, or of an improvement in endothelial function, is fascinating and future studies to compare the renal effects of GLP-1 receptor agonists and tirzepatide should be planned rapidly.

I declare no competing interests.

Anna Solini
anna.solini@med.unipi.it

Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa I-56126, Italy

1 Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021; 398: 1811–24.

2 Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol 2022; published online Sept 21. https://doi.org/10.1016/S2213-8587(22)00243-1.

3 Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9: 653–62.

4 Udin TB, Messey E, Butten DC, Brownstein MJ, Renner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993; 133: 2861–70.

5 Karagiannis T, Avgertinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia 2022; 65: 1251–61.

6 Patoulas D, Katsimardou A, Boulmpou A, et al. Meta-analysis of the effect of dual GIP and GLP-1 receptor agonists on blood pressure levels in patients with type 2 diabetes mellitus. J Hypertens 2022; 40(suppl 1): e300–01.

7 Tuttle KR, McKinney TD, Davidson JA, Anglin G, Harper KD, Botros FT. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diabetes Obes Metab 2017; 19: 436–41.

8 Norris KC, Smoyer KE, Rolland C, Van der Vaart J, Grubb EB. Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review. BMC Nephrol 2018; 19: 36.

9 Urua S, Quinnan T, Landby J, Martin J, Loghin C. Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide. Clin Pharmacokinet 2021; 60: 1049–59.

Rise in diabetic ketoacidosis during the COVID-19 pandemic: several questions remain

Diabetic ketoacidosis is a life-threatening metabolic crisis that can occur at presentation of type 1 diabetes, with acute (potentially fatal) complications including cerebral oedema and arrhythmias, and longer-term evidence of worsening glycaemic control and neurocognitive deficits in those presenting with diabetic ketoacidosis compared to those presenting without.

During the COVID-19 pandemic, an excess of diabetic ketoacidosis in people with newly diagnosed diabetes was noted across all age groups.1 Although there was no shortage of theories as to how SARS-CoV-2 might have contributed to the rise in diabetic ketoacidosis (or indeed the subsequent apparent increase in incidence of type 1 diabetes)2–4), a careful analysis of trends in diabetic ketoacidosis during the COVID-19 pandemic, framed in the context of pre-pandemic evidence, was lacking.

In their study in The Lancet Diabetes & Endocrinology, Niels Birkebaek and colleagues’ address this knowledge gap by analysing trends in diabetic ketoacidosis at diagnosis of type 1 diabetes in the largest cohort to date, comprising 104 290 children from 13 national diabetes registries. The authors first studied the pre-pandemic period (2006–19), in which 27·3% of paediatric presentations of type 1 diabetes occurred with diabetic ketoacidosis, but they noted a significant year-on-year rise in diabetic ketoacidosis prevalence (mean 1·6% [95% CI 1·3–1·9] increase per year). A higher prevalence of diabetic ketoacidosis was observed in children younger than 6 years and in female individuals.

During the pandemic, the proportion of diabetic ketoacidosis presentations rose significantly (39·4% [95% CI 34·0–45·6] in 2020 and 38·9% [33·6–45·0] in 2021) and was in excess of the predicted year-on-year rise in diabetic ketoacidosis prevalence (mean 1·6% [95% CI 1·3–1·9] increase per year). A higher prevalence of diabetic ketoacidosis was observed in children younger than 6 years and in female individuals.

The authors concluded that the pandemic created the perfect storm of conditions amplifying the pre-pandemic trend favouring presentation of diabetic ketoacidosis at first diagnosis of type 1 diabetes in children.
Although it is not possible to ascertain whether the excess diabetic ketoacidosis prevalence observed during the pandemic represented higher prevalence in a population with similar type 1 diabetes incidence or a higher incidence of type 1 diabetes per se, this study has several strengths. First, the large sample size, geographical coverage, and use of both 2020 and 2021 data increases confidence that the trend observed is genuine. Second, a focus on children in whom a presentation with diabetic ketoacidosis is likely to signify a new diagnosis of type 1 diabetes is also a strength as cohorts comprising adults might have other diabetes diagnoses. Third, the novel finding of an association between lockdown stringency and diabetic ketoacidosis, but not COVID-19 mortality, suggests that the excess prevalence of diabetic ketoacidosis might be dissociated from direct SARS-CoV-2 infection. Of course, mortality itself could be a poor surrogate for the prevalence of SARS-CoV-2 infection in children, who are more likely to have asymptomatic infection and less likely to develop severe COVID-19.

This study has important implications. That the prevalence of diabetic ketoacidosis was increasing before the pandemic has been reported previously and been shown to be associated with vulnerable groups (eg, people from socioeconomically deprived and minority ethnic backgrounds). Although there currently is no treatment to prevent type 1 diabetes, efforts to improve recognition of the often-vague presenting symptoms by health-care professionals and greater awareness of type 1 diabetes through targeted public health campaigns are crucial. The pathogenesis of type 1 diabetes involves an environmental trigger followed by a sequential decline in beta-cell function to the point of severe insulin deficiency, when diabetic ketoacidosis is unavoidable. Symptoms of hyperglycaemia can develop ahead of this final stage, so a first presentation of diabetic ketoacidosis signifies either a delay in seeking medical attention for symptoms or a delay by health-care professionals in identification of those symptoms as being indicative of type 1 diabetes, or a combination of both.

It is now well documented that the provision of routine health-care services across several countries was curtailed during the pandemic, with additional delays in people presenting to health-care providers due to a fear of contracting SARS-CoV-2. One could reasonably conclude that a primary factor explaining the excess prevalence of diabetic ketoacidosis during the pandemic might be related to these practical issues and this theory is certainly supported by the present analysis.

However, against this backdrop is the hypothesis that SARS-CoV-2 itself might have directly injured pancreatic beta cells, leading to excess cases of insulin-requiring diabetes and diabetic ketoacidosis during the pandemic. Several analyses have shown an increase in paediatric type 1 diabetes cases during the pandemic. Although a direct effect of SARS-CoV-2 on the pancreas is a tantalising hypothesis, other explanations such as a viral infection triggering type 1 diabetes in those susceptible, or indeed the rise in obesity during the pandemic unmasking type 1 diabetes earlier in the disease trajectory, must be considered. Segregating these inter-mingling factors from one another is complex.

For now, many questions relating to the rising prevalence of diabetic ketoacidosis during the pandemic remain unanswered and clarity will only emerge with time. Central to this endeavour are analyses of population-level curated datasets, longitudinal follow-up studies, and analysis of trends well beyond the pandemic period. Collaborative, multi-ethnic, real-world data collection will eventually provide these answers; we will wait patiently until then.

I am a trustee of the Diabetes Research and Wellness Foundation and have a grant in support of an investigator-initiated study from DexCom.

Shivani Misra
s.misra@imperial.ac.uk
Division of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK; Department of Diabetes, Endocrinology and Metabolism, Imperial College Healthcare NHS Trust, London, UK

1 Duca LM, Reboissin BA, Piloker C, et al. Diabetic ketoacidosis at diagnosis of type 1 diabetes and glycemic control over time: the SEARCH for diabetes in youth study. Pediatr Diabetes 2019; 20: 172–79.

2 Ghetti S, Kupfermann N, Rewers A, et al. Cognitive function following diabetic ketoacidosis in children with new-onset or previously diagnosed type 1 diabetes. Diabetes Care 2020; 43: 2768–75.

3 Misra S, Barron E, Vamos E, et al. Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. Lancet Diabetes Endocrinol 2021; 9: 671–80.

4 Gottesman BL, Yu J, Tanaka C, Longhurst CA, Kim JJ. Incidence of new-onset type 1 diabetes among US children during the COVID-19 global pandemic. Jama Pediatr 2022; 176: 414–15.

5 Kamrath C, Rosenbauer J, Eckert AJ, et al. Incidence of type 1 diabetes in children and adolescents during the COVID-19 pandemic in Germany: results from the DPV registry. Diabetes Care 2022; 45: 1762–71.

6 Barrett CE, Koyama AK, Alvarez P, et al. Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years — United States, March 1, 2020–June 28, 2021. MMWR Morb Mortal Wkly Rep 2022; 71: 59–65.
New metrics to support diabetes education and advocacy

No endocrinologist, epidemiologist, or health system manager needs to be told that the prevalence of type 2 diabetes is on the rise. Yet, despite this awareness among key stakeholders and the initiation of national diabetes prevention programmes in some countries, the prevalence of type 2 diabetes and its accompanying disease burden continue to inexorably increase, and the condition is now considered a non-transmissible pandemic.1

In most countries, this increase in prevalence is due to a continuing rise in diabetes incidence. However, even in countries where age-standardised incidence appears to be in decline, prevalence has risen. Population ageing explains much of this increase; the rest is partly explained by the successful prevention of early deaths caused by diabetes complications, notably cardiovascular ones.

More effective strategies for the prevention of diabetes are thus sorely needed. Stimulated by the success of landmark diabetes prevention trials,2,3 the most frequently advocated approach entails screening to identify people at high risk of developing diabetes and then intervening to prevent the disease. However, success, although present, has been more limited than that projected by the initial trials, in great part due to difficulty in enrolling a relevant fraction of those at risk.4

Population-based prevention, such as through food taxes and subsidies, restrictions on the advertising of unhealthy food, and social marketing, appears to offer greater promise than screening.5 Still, the adoption of these approaches has been constrained by political processes that favour lobbying by industry over science and popular desires and by the vision that maintaining the unlevel playing field of food distribution and advertising somehow guarantees liberty of expression and choice and economic efficiency.

The question thus is how to bring prevention into favour. A meaningful step in this direction is to help the public and decision makers to realise that the burden imposed by diabetes might come to affect them personally. Diabetes prevalence estimates, unfortunately, do not help much in this regard. Estimates in adults are usually between 5% and 15%—ie, from a 1 in 20 to a 1 in 7 chance of the average adult having diabetes.5 When considering all ages, estimates are even lower, usually ranging from 3% to 10%. However, many people who are counted in the denominators, being children or young adults, are currently at very low risk. The risk of having diabetes at one point in time does not adequately convey the true burden.

A new set of metrics—the lifetime risk of developing diabetes, the life expectancy of people with diabetes, and years of life lost to diabetes—has the potential to improve recognition of individual risk and burden. Initially reported for only a few settings, in The Lancet Diabetes & Endocrinology, Dunya Tomic and colleagues’ now present these indicators in relation to type 2 diabetes for populations in 23 high-income jurisdictions. The metrics offer a perspective of diabetes burden not gained from previous prevalence data alone (table). Lifetime risk ranged from 16.3% to 59.6% and

### Table: Diabetes prevalence and lifetime risk by country

| Country | Prevalence Men | Lifetime risk Men | Lifetime risk Women |
|---------|----------------|-------------------|---------------------|
| UK      | 8.2%           | 27.0%             | 18.6%               |
| USA     | 13.6%          | 33.1%             | 37.1%               |
| Japan   | 11.8%          | 52.3%             | 37.6%               |
| Taiwan  | 13.1%          | 49.3%             | 49.3%               |
| Brazil  | 10.5%          | 26.3%†            | 28.0%†              |
| Mexico  | 16.9%          | 34.8%             | 41.4%               |

Data on diabetes prevalence were sourced from the International Diabetes Federation Diabetes Atlas. Data on lifetime risk were sourced from three articles.7,9

Ages 20–79 years. 1 From age 35 years.